FDA Drug Recalls

Recalls / Class II

Class IID-0579-2023

Product

Heparin Sodium, 25,000 USP units per 250mL, (100 USP units per mL) in 5% Dextrose injection, 250 ml Excel Container, B. Braun Medical Inc. Bethlehem, PA 18018, USA; API from Spain NDC: 0264-9587-20,

Brand name
Heparin Sodium In Dextrose
Generic name
Heparin Sodium And Dextrose
Active ingredients
Dextrose Monohydrate, Heparin Sodium
Route
Intravenous
NDCs
0264-9567, 0264-9577, 0264-9587
FDA application
NDA019952
Affected lot / code info
Lot Number: J1P154N, Exp: 31 May, 2023,

Why it was recalled

Subpotent: Low anti-factor IIa Potency.

Recalling firm

Firm
B. Braun Medical Inc
Manufacturer
B. Braun Medical Inc.
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
2525 Mcgaw Ave, N/A, Irvine, California 92614-5841

Distribution

Quantity
1,380
Distribution pattern
Nationwide in the USA

Timeline

Recall initiated
2023-05-09
FDA classified
2023-05-16
Posted by FDA
2023-05-24
Terminated
2024-03-14
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-0579-2023. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.